192 related articles for article (PubMed ID: 11235605)
1. New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).
Dharmalingam M; Kumar P
J Assoc Physicians India; 2001 Jan; 49 Spec No():46-9. PubMed ID: 11235605
[No Abstract] [Full Text] [Related]
2. Novel pharmacologic agents for type 2 diabetes.
Uwaifo GI; Ratner RE
Endocrinol Metab Clin North Am; 2005 Mar; 34(1):155-97. PubMed ID: 15752927
[TBL] [Abstract][Full Text] [Related]
3. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
Purnell JQ; Weyer C
Treat Endocrinol; 2003; 2(1):33-47. PubMed ID: 15871553
[TBL] [Abstract][Full Text] [Related]
4. Research advances in the treatment of type 2 diabetes mellitus.
Caro J; Wishner KL
Int J Clin Pract Suppl; 1999 Sep; 107():23-33. PubMed ID: 10692729
[No Abstract] [Full Text] [Related]
5. New treatments for patients with type 2 diabetes mellitus.
Wolffenbuttel BH; Graal MB
Postgrad Med J; 1996 Nov; 72(853):657-62. PubMed ID: 8944206
[TBL] [Abstract][Full Text] [Related]
6. Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.
Zander M; Christiansen A; Madsbad S; Holst JJ
Diabetes Care; 2004 Aug; 27(8):1910-4. PubMed ID: 15277416
[TBL] [Abstract][Full Text] [Related]
7. Are you up-to-date on diabetes medications?
Scemons D
Nursing; 2007 Jul; 37(7):45-9; quiz 49-50. PubMed ID: 17603373
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological management of type 2 diabetes mellitus: an update.
El-Kaissi S; Sherbeeni S
Curr Diabetes Rev; 2011 Nov; 7(6):392-405. PubMed ID: 21846326
[TBL] [Abstract][Full Text] [Related]
9. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients.
Juntti-Berggren L; Pigon J; Karpe F; Hamsten A; Gutniak M; Vignati L; Efendic S
Diabetes Care; 1996 Nov; 19(11):1200-6. PubMed ID: 8908380
[TBL] [Abstract][Full Text] [Related]
10. The use of insulin secretagogues in the treatment of type 2 diabetes.
Luna B; Hughes AT; Feinglos MN
Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
[TBL] [Abstract][Full Text] [Related]
11. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Hermansen K; Mortensen LS
Drug Saf; 2007; 30(12):1127-42. PubMed ID: 18035865
[TBL] [Abstract][Full Text] [Related]
12. [Future targets in the treatment of type 2 diabetes].
Stingl H; Roden M
Wien Klin Wochenschr; 2004 Apr; 116(7-8):217-29. PubMed ID: 15143860
[TBL] [Abstract][Full Text] [Related]
13. [Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
Reblin T; Seidel D; Stein D; Görtz A; Lander T
MMW Fortschr Med; 2003 May; 145(19):41. PubMed ID: 12813977
[No Abstract] [Full Text] [Related]
14. [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
Göke B; Hoppe B; Konrad A; Schirra J
Pharm Unserer Zeit; 2002; 31(3):294-9. PubMed ID: 12071126
[No Abstract] [Full Text] [Related]
15. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
Kiayias JA; Vlachou ED; Theodosopoulou E; Lakka-Papadodima E
Diabetes Care; 2002 Jul; 25(7):1251-2. PubMed ID: 12087036
[No Abstract] [Full Text] [Related]
18. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Nauck MA
Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
